IMPACT SCORE JOURNAL RANKING CONFERENCE RANKING Conferences Journals Workshops Seminars SYMPOSIUMS MEETINGS BLOG LaTeX 5G Tutorial Free Tools

Search About Journals, Conferences, and Book Series

Journal for ImmunoTherapy of Cancer

Impact, Factor and Metrics, Impact Score, Ranking, h-index, SJR, Rating, Publisher, ISSN, and More

Last Updated on June 27, 2025

Impact Score

2024-2025

9.10

h-Index

2024-2025

 136

Rank

2024-2025

 377

SJR

2024-2025

 4.22

Note: The impact score or impact index shown here is equivalent to the average number of times documents published in a journal/conference in the past two years have been cited in the current year (i.e., Cites / Doc. (2 years)). It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Please refer to the Web of Science data source to check the exact journal impact factor ™ (Thomson Reuters) metric.

Important Metrics and Factor

Title Journal for ImmunoTherapy of Cancer
Abbreviation J. ImmunoTher. Cancer
Publication Type Journal
Subject Area, Categories, Scope Cancer Research (Q1); Immunology (Q1); Immunology and Allergy (Q1); Molecular Medicine (Q1); Oncology (Q1); Pharmacology (Q1)
h-index 136
Overall Rank/Ranking 377
SCImago Journal Rank (SJR) 4.22
Impact Score 9.10
Publisher BMJ Publishing Group
Country United Kingdom
ISSN 20511426
Best Quartile Q1
Coverage History 2013-2025




About Journal for ImmunoTherapy of Cancer


Journal for ImmunoTherapy of Cancer is a journal covering the technologies/fields/categories related to Cancer Research (Q1); Immunology (Q1); Immunology and Allergy (Q1); Molecular Medicine (Q1); Oncology (Q1); Pharmacology (Q1). It is published by BMJ Publishing Group. The overall rank of Journal for ImmunoTherapy of Cancer is 377. According to SCImago Journal Rank (SJR), this journal is ranked 4.22. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 136. The best quartile for this journal is Q1.

The ISSN of Journal for ImmunoTherapy of Cancer journal is 20511426. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Journal for ImmunoTherapy of Cancer is cited by a total of 14439 articles during the last 3 years (Preceding 2024).


Journal for ImmunoTherapy of Cancer Impact IF 2024-2025


The Impact IF 2024 of Journal for ImmunoTherapy of Cancer is 9.10, which is computed in 2025 as per its definition. Journal for ImmunoTherapy of Cancer IF is increased by a factor of 0.39 and approximate percentage change is 4.48% when compared to preceding year 2023, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Table Setting

Journal for ImmunoTherapy of Cancer Impact IF 2025 Prediction


Impact IF 2024 of Journal for ImmunoTherapy of Cancer is 9.10. If the same upward trend persists, Impact IF may rise in 2025 as well.


Impact IF Trend


Year wise Impact IF of Journal for ImmunoTherapy of Cancer. Based on Scopus data.


Year Impact IF
2025/2026 Coming Soon
2024 9.10
2023 8.71
2022 8.88
2021 10.69
2020 11.40
2019 9.47
2018 8.00
2017 5.88
2016 5.18
2015 5.03
2014 2.24

Journal for ImmunoTherapy of Cancer h-index


  Table Setting

Journal for ImmunoTherapy of Cancer has an h-index of 136. It means 136 articles of this journal have more than 136 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.




Journal for ImmunoTherapy of Cancer ISSN


The ISSN of Journal for ImmunoTherapy of Cancer is 20511426. ISSN stands for International Standard Serial Number.

An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.

Table Setting

Journal for ImmunoTherapy of Cancer Rank and SCImago Journal Rank (SJR)


The overall rank of Journal for ImmunoTherapy of Cancer is 377. According to SCImago Journal Rank (SJR), this journal is ranked 4.22. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.

SJR of Journal for ImmunoTherapy of Cancer by Year


Year SJR
2025/2026 Coming Soon
2024 4.22
2023 3.728
2022 3.403
2021 3.450
2020 5.060
2019 4.194
2018 3.337
2017 2.798
2016 2.668
2015 1.929
2014 0.486

Ranking of Journal for ImmunoTherapy of Cancer by Year


Year Ranking
2025/2026 Coming Soon
2024 377
2023 446
2022 494
2021 475
2020 285
2019 359
2018 546
2017 739
2016 807
2015 1547
2014 9184

Journal for ImmunoTherapy of Cancer Publisher


Table Setting

Journal for ImmunoTherapy of Cancer is published by BMJ Publishing Group. It's publishing house is located in United Kingdom. Coverage history of this journal is as following: 2013-2025. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.


Call For Papers


Visit the official website of the journal/conference to check the further details about the call for papers.


Abbreviation


The IS0 4 standard abbreviation of Journal for ImmunoTherapy of Cancer is J. ImmunoTher. Cancer. This abbreviation ('J. ImmunoTher. Cancer') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.

ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.


How to publish in Journal for ImmunoTherapy of Cancer


If your research field is/are related to Cancer Research (Q1); Immunology (Q1); Immunology and Allergy (Q1); Molecular Medicine (Q1); Oncology (Q1); Pharmacology (Q1), then please visit the official website of this journal.


Acceptance Rate


The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.

  • The demand or interest of researchers/scientists in publishing in a specific Journal/Conference.
  • Peer review complexity and timeline.
  • The mix of unsolicited and invited submissions.
  • The time it takes from manuscript submission to final publication.
  • And Many More.

It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.

The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.



Frequently Asked Questions (FAQs)


What's the latest impact IF of the Journal for ImmunoTherapy of Cancer?

Journal for ImmunoTherapy of Cancer latest impact IF is 9.10. It's evaluated in the year 2024. The highest and the lowest impact IF or impact score of this journal are 11.40 (2020) and 2.24 (2014), respectively, in the last 11 years. Moreover, its average IS is 7.69 in the previous 11 years.


What's the SCImago Journal Rank (SJR) of the Journal for ImmunoTherapy of Cancer?

The Journal for ImmunoTherapy of Cancer has an SJR (SCImago Journal Rank) of 4.22, according to the latest data. It is computed in the year 2025. In the past 11 years, this journal has recorded a range of SJR, with the highest being 5.060 in 2020 and the lowest being 0.486 in 2014. Furthermore, the average SJR of the Journal for ImmunoTherapy of Cancer over the previous 11-year period stands at 7.69.


What's the latest h-index of the Journal for ImmunoTherapy of Cancer?

The latest h-index of the Journal for ImmunoTherapy of Cancer is 136.


Who's the publisher of the Journal for ImmunoTherapy of Cancer?

The Journal for ImmunoTherapy of Cancer is published by the BMJ Publishing Group, with its country of publication being the United Kingdom.


What's the current ranking of the Journal for ImmunoTherapy of Cancer?

The Journal for ImmunoTherapy of Cancer is currently ranked 377 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 11 years, this journal has experienced varying rankings, reaching its highest position of 285 in 2020 and its lowest position of 9184 in 2014.


What's the abbreviation or short name for the Journal for ImmunoTherapy of Cancer?

The standard ISO4 abbreviation for the Journal for ImmunoTherapy of Cancer is J. ImmunoTher. Cancer.


Is the "Journal for ImmunoTherapy of Cancer" classified as a Journal, Conference and Proceedings, Trade Journal or Book Series?

Journal for ImmunoTherapy of Cancer is classified as a journal that the BMJ Publishing Group publishes.


What's the scope or major areas of the Journal for ImmunoTherapy of Cancer?

The Journal for ImmunoTherapy of Cancer encompasses the following areas:

  • Cancer Research
  • Immunology
  • Immunology and Allergy
  • Molecular Medicine
  • Oncology
  • Pharmacology

For a more comprehensive understanding of its scope, check the official website of this journal.


What's the ISSN of the Journal for ImmunoTherapy of Cancer?

The Journal for ImmunoTherapy of Cancer is assigned the following International Standard Serial Numbers (ISSN): 20511426.


What's the best quartile of the Journal for ImmunoTherapy of Cancer?

The best quartile for the Journal for ImmunoTherapy of Cancer is Q1 (2024).


What's the coverage history of the Journal for ImmunoTherapy of Cancer?

The Journal for ImmunoTherapy of Cancer coverage history can be summarized as follows: 2013-2025.


Credits and Sources


  • Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
  • Journal Impact Factor, https://clarivate.com/



Impact Score, h-Index, and Other Important Details of These Journals, Conferences, and Books


Journal/Conference/Workshop/Book Title Type Ranking Publisher h-index Impact Score
European Union Politics journal 1953 SAGE Publications Ltd 79 3.71
Journal of Geriatric Physical Therapy journal 8686 Lippincott Williams and Wilkins Ltd. 53 1.55
Air and Space Power Journal (discontinued) journal 28397 AU Press 9 0.20
Marine Biology Research journal 14618 Taylor and Francis Ltd. 47 1.21
Journal of Education and Work journal 8987 Brill Academic Publishers 47 2.08
International Journal of Research and Method in Education journal 6367 Taylor and Francis Ltd. 41 3.31
Rinsan Shikenj Oha/Journal of the Hokkaido Forest Products Research Institute journal 29148 Hoikkaido Forest Products Research Institute 4 0.00
European Journal of Cancer, Supplement journal 13149 Elsevier Ltd 30 0.00
Transactions on Embedded Computing Systems journal 7171 Association for Computing Machinery 67 3.13
East African journal of public health journal 19634 East African Public Health Association 23 0.00

Check complete list




Year wise Impact Score (IS) of Journal for ImmunoTherapy of Cancer

Impact Score Table

Year Impact Score (IS)
2025/2026 Coming Soon
2024 9.10
2023 8.71
2022 8.88
2021 10.69
2020 11.40
2019 9.47
2018 8.00
2017 5.88
2016 5.18
2015 5.03
2014 2.24



Top Journals/Conferences in Cancer Research

Nature Reviews Cancer
Nature Publishing Group | United Kingdom

Cancer Cell
Cell Press | United States

Signal Transduction and Targeted Therapy
Springer Nature | United Kingdom

Nature Cancer
Nature Research | United States

Journal of Clinical Oncology
Lippincott Williams and Wilkins | United States

Journal of Hematology and Oncology
BioMed Central Ltd | United Kingdom

Molecular Cancer
BioMed Central Ltd | United Kingdom

JAMA Oncology
American Medical Association | United States

Cell Host and Microbe
Cell Press | United States

Neuro-Oncology
Oxford University Press | United Kingdom

See All

Top Journals/Conferences in Immunology

Nature Reviews Immunology
Nature Research | United Kingdom

Annual Review of Immunology
Annual Reviews Inc. | United States

Nature Reviews Microbiology
Nature Research | United Kingdom

Immunity
Cell Press | United States

Nature Immunology
Nature Research | United Kingdom

Science immunology
American Association for the Advancement of Science | United States

Cell Host and Microbe
Cell Press | United States

Nature Microbiology
Nature Research | United Kingdom

Cellular and Molecular Immunology
Springer Nature | United Kingdom

Journal of Experimental Medicine
Rockefeller University Press | United States

See All

Top Journals/Conferences in Immunology and Allergy

Nature Reviews Immunology
Nature Research | United Kingdom

Annual Review of Immunology
Annual Reviews Inc. | United States

Immunity
Cell Press | United States

Nature Immunology
Nature Research | United Kingdom

Science immunology
American Association for the Advancement of Science | United States

Cellular and Molecular Immunology
Springer Nature | United Kingdom

Journal of Experimental Medicine
Rockefeller University Press | United States

Annals of the Rheumatic Diseases
Elsevier B.V. | United Kingdom

Journal of Allergy and Clinical Immunology
Elsevier Inc. | United States

Trends in Immunology
Elsevier Ltd | United Kingdom

See All

Top Journals/Conferences in Molecular Medicine

Nature Biotechnology
Nature Research | United Kingdom

Cell Stem Cell
Cell Press | United States

Molecular Cancer
BioMed Central Ltd | United Kingdom

Pharmacological Reviews
Elsevier Inc. | United States

Genome Medicine
BioMed Central Ltd | United Kingdom

Molecular Therapy
Cell Press | United States

Experimental and Molecular Medicine
Springer Nature | United Kingdom

Trends in Molecular Medicine
Elsevier Ltd | United Kingdom

EMBO Molecular Medicine
Springer Science and Business Media Deutschland GmbH | United Kingdom

Biomarker Research
BioMed Central Ltd | United Kingdom

See All

Top Journals/Conferences in Oncology

Ca-A Cancer Journal for Clinicians
John Wiley and Sons Inc | United States

Nature Reviews Clinical Oncology
Nature Publishing Group | United Kingdom

Nature Reviews Cancer
Nature Publishing Group | United Kingdom

Annals of Oncology
Elsevier Ltd | United Kingdom

Cancer Cell
Cell Press | United States

Nature Cancer
Nature Research | United States

Lancet Oncology, The
Elsevier Ltd | United Kingdom

Journal of Clinical Oncology
Lippincott Williams and Wilkins | United States

Journal of Hematology and Oncology
BioMed Central Ltd | United Kingdom

Molecular Cancer
BioMed Central Ltd | United Kingdom

See All

Top Journals/Conferences in Pharmacology

Nature Reviews Drug Discovery
Nature Research | United Kingdom

Pharmacological Reviews
Elsevier Inc. | United States

Drug Resistance Updates
Churchill Livingstone | United Kingdom

Annual Review of Pharmacology and Toxicology
Annual Reviews Inc. | United States

Molecular Therapy
Cell Press | United States

Pharmacology and Therapeutics
Elsevier Inc. | United States

Trends in Pharmacological Sciences
Elsevier Ltd | United Kingdom

Acta Pharmaceutica Sinica B
Chinese Academy of Medical Sciences | China

Theranostics
Ivyspring International Publisher | Australia

Drugs
| Switzerland

See All